To further determine whether Tregs are involved in resistance to PD-1 treatment, researchers targeted deletion Tregs with anti-CD25 antibodies, which restored anti-PD-L1 antibody-mediated anti-tumor immunity and contributed to the rejection of established tumors [173]. Here, PDCD1 is linked to neoplasm.